tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

SYRE Stock Latest News

Spyre Therapeutics Accelerates SKYLINE Trial and Bolsters Leadership
Company AnnouncementsSpyre Therapeutics Accelerates SKYLINE Trial and Bolsters Leadership
19h ago
8K
SYRE
Spyre Therapeutics highlights 2026 priorities, appoints Cheveln as CCO
PremiumThe Fly
Spyre Therapeutics highlights 2026 priorities, appoints Cheveln as CCO
19h ago
SYRE
Spyre Therapeutics: TL1A Blockade Opportunity in Rheumatology Underpins Buy Rating and $64 Target
PremiumRatings
Spyre Therapeutics: TL1A Blockade Opportunity in Rheumatology Underpins Buy Rating and $64 Target
8d ago
SYRE
Spyre Therapeutics falls -7.4%
PremiumThe Fly
Spyre Therapeutics falls -7.4%
11d ago
SYRE
Spyre Therapeutics: TL1A-Driven Inflammatory Arthritis Opportunity Underpins Buy Rating and $64 Target
PremiumRatings
Spyre Therapeutics: TL1A-Driven Inflammatory Arthritis Opportunity Underpins Buy Rating and $64 Target
22d ago
SYRE
Spyre Therapeutics initiated with an Outperform at Mizuho
PremiumThe FlySpyre Therapeutics initiated with an Outperform at Mizuho
27d ago
SYRE
Spyre Therapeutics initiated with a Buy at Citi
Premium
The Fly
Spyre Therapeutics initiated with a Buy at Citi
27d ago
SYRE
Buy Rating for Spyre Therapeutics Driven by Strong Stock Performance and Promising Clinical Developments
Premium
Ratings
Buy Rating for Spyre Therapeutics Driven by Strong Stock Performance and Promising Clinical Developments
1M ago
SYRE
Carvana initiated, Zscaler downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Carvana initiated, Zscaler downgraded: Wall Street’s top analyst calls
1M ago
ZS
CCI
3 Best Stocks to Buy Now, 12/1/2025, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Now, 12/1/2025, According to Top Analysts
1M ago
KTOS
LENZ
Spyre Therapeutics upgraded to Buy from Hold at JonesResearch
PremiumThe Fly
Spyre Therapeutics upgraded to Buy from Hold at JonesResearch
1M ago
SYRE
Spyre Therapeutics: Promising Innovations and Strong Financials Justify Buy Rating
PremiumRatings
Spyre Therapeutics: Promising Innovations and Strong Financials Justify Buy Rating
2M ago
SYRE
Spyre Therapeutics Reports Q3 2025 Financial Results
PremiumCompany AnnouncementsSpyre Therapeutics Reports Q3 2025 Financial Results
2M ago
SYRE
Spyre Therapeutics reports Q3 EPS (15c), consensus (74c)
Premium
The Fly
Spyre Therapeutics reports Q3 EPS (15c), consensus (74c)
2M ago
SYRE
Spyre Therapeutics Reports Positive Phase 1 Results for SPY003
Premium
Company Announcements
Spyre Therapeutics Reports Positive Phase 1 Results for SPY003
2M ago
8K
SYRE
Spyre Therapeutics Advances in Ulcerative Colitis Treatment Study
PremiumCompany Announcements
Spyre Therapeutics Advances in Ulcerative Colitis Treatment Study
3M ago
SYRE
Spyre Therapeutics Advances Phase 2 Study of SPY072 for Rheumatic Diseases
PremiumCompany Announcements
Spyre Therapeutics Advances Phase 2 Study of SPY072 for Rheumatic Diseases
3M ago
SYRE
Spyre Therapeutics’ SPY002-091 Study: A Potential Game-Changer in Drug Development
PremiumCompany Announcements
Spyre Therapeutics’ SPY002-091 Study: A Potential Game-Changer in Drug Development
3M ago
SYRE
Spyre Therapeutics Advances with Phase 1 Study of SPY003-207
PremiumCompany Announcements
Spyre Therapeutics Advances with Phase 1 Study of SPY003-207
3M ago
SYRE
Spyre Therapeutics Advances with Phase 1 Study of SPY002-072
PremiumCompany AnnouncementsSpyre Therapeutics Advances with Phase 1 Study of SPY002-072
3M ago
SYRE
Spyre Therapeutics Announces Public Stock Offering
Premium
Company Announcements
Spyre Therapeutics Announces Public Stock Offering
3M ago
8K
SYRE
Spyre Therapeutics 14.86M share Spot Secondary priced at $18.50
Premium
The Fly
Spyre Therapeutics 14.86M share Spot Secondary priced at $18.50
3M ago
SYRE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >